Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- COCP
- Price
- 1.31
- Stock movement up
- +- (%)
- Company name
- Cocrystal Pharma Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 13.33M
- Ent value
- 3.84M
- Price/Sales
- 92.55
- Price/Book
- 1.05
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -38.40%
- 1 year return
- -10.27%
- 3 year return
- -40.57%
- 5 year return
- -36.47%
- 10 year return
- -43.86%
Last updated: 2025-04-18
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
COCP does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 92.55 |
| Price to Book | 1.05 |
| EV to Sales | 26.65 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 10.17M |
| EPS (TTM) | -1.84 |
| FCF per share (TTM) | -1.60 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 144.00K |
| Gross profit (TTM) | 4.00K |
| Operating income (TTM) | -20.31M |
| Net income (TTM) | -18.70M |
| EPS (TTM) | -1.84 |
| EPS (1y forward) | -2.21 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 2.78% |
| Operating margin (TTM) | -14106.94% |
| Profit margin (TTM) | -12987.50% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 13.02M |
| Net receivables | 652.00K |
| Total current assets | 14.26M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 16.23M |
| Accounts payable | 859.00K |
| Short/Current long term debt | 1.88M |
| Total current liabilities | 1.95M |
| Total liabilities | 3.53M |
| Shareholder's equity | 12.70M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -16.19M |
| Capital expenditures (TTM) | 65.13K |
| Free cash flow (TTM) | -16.25M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -147.23% |
| Return on Assets | -115.21% |
| Return on Invested Capital | -143.91% |
| Cash Return on Invested Capital | -125.07% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 1.32 |
| Daily high | 1.34 |
| Daily low | 1.31 |
| Daily Volume | 2K |
| All-time high | 1980.00 |
| 1y analyst estimate | 8.00 |
| Beta | 1.45 |
| EPS (TTM) | -1.84 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 12 May 2025 |
Downside potential
Loading...
Downside potential data
| COCP | S&P500 | |
| Current price drop from All-time high | -99.93% | -14.12% |
| Highest price drop | -99.99% | -56.47% |
| Date of highest drop | 5 Oct 2022 | 9 Mar 2009 |
| Avg drop from high | -94.72% | -11.07% |
| Avg time to new high | 1506 days | 12 days |
| Max time to new high | 3010 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
13.33M
Marketcap category
Small-cap
Description
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that has completed Phase I clinical trial for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.
Employees
12
Investor relations
-
SEC filings
CEO
Gary L. Wilcox
Country
USA
City
Bothell
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
No events found
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page